Latest
-
Life & Health
Australia’s biosimilar gap could close if the government acts now
Samsung Bioepis and Organon expanded their partnership to bring a fourth product to Australia as Canberra weighs making biosimilars the default for new patients, potentially freeing A$1.5 billion in PBS savings over five years.
-
-
-
-
-
-

























































